Browse articles from the EyeWorld March 2021 issue. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
Durysta, the sustained-release bimatoprost implant, 10 mcg (Allergan), has been available with FDA approval in the U.S. market for a year now. EyeWorld spoke with two physicians who started offering it as an option to their patients to hear about their experience thus far.
EyeWorld spoke with several glaucoma specialists who discussed changes they’ve noticed in glaucoma as well as in their own practices due to the COVID-19 pandemic. They shared how they’ve adapted to continue patient care and described the changes they think are here to stay post-pandemic.
This may not be the year that COVID-19 “goes away” but rather the year that we use what’s been learned to dig in for the next phase of a longer fight than was ever expected. But even in this still hunkering-down year, practices have to continue to pursue their development plans.
Developing a 2021 medical marketing strategy that is designed to meet the needs of patients in the COVID-19 era requires a change of mindset. Place yourself in patients’ shoes, start identifying relatable 2021 experiences, and convert those into profitable marketing opportunities, as well as chances to improve patient care.
EyeWorld reached out to ASCRS members and members of the EyeWorld Editorial Board to ask how the pandemic has changed practices a year after the historic shutdown of elective medical procedures.